Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina    ILMN

ILLUMINA (ILMN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies

Anaïs Lozach

 
 
share with twitter share with LinkedIn share with facebook
share via e-mail

There is still some upside potential

Strategy published on 10/06/2017 | 14:09
long trade
Live
Entry price : 205.97$ | Target : 230$ | Stop-loss : 193.7$ | Potential : 11.67%
The timing appears opportune to go long in shares of Illumina as we anticipate another pick-up in the underlying trend.
Investors have an opportunity to buy the stock and target the $ 230.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Historically, the company has been releasing figures that are above expectations.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The stock is in a well-established, long-term rising trend above the technical support level at 160.42 USD

Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 210.72.
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.2 times its estimated earnings per share for the ongoing year.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart
Subsector Advanced Medical Equipment & Technology - NEC
1st jan.Capitalisation (M$)Investor Rating
ILLUMINA61.61%30 171
THERMO FISHER SCIENTIFIC IN..36.37%76 300
DANAHER11.56%59 834
BOSTON SCIENTIFIC CORPORATI..36.11%40 011
INTUITIVE SURGICAL71.38%39 404
ROYAL PHILIPS19.34%37 974
CERNER55.31%23 900
EDWARDS LIFESCIENCES CORP15.53%22 915
AGILENT TECHNOLOGIES INC47.04%21 534
WATERS CORPORATION38.25%14 739
OLYMPUS CORP-1.36%12 170
Autres valeurs du secteur
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2017 2 683 M
EBIT 2017 646 M
Net income 2017 792 M
Finance 2017 821 M
Yield 2017 -
P/E ratio 2017 38,29
P/E ratio 2018 50,59
EV / Sales 2017 10,9x
EV / Sales 2018 9,50x
Capitalization 30 171 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ILLUMINA
Duration : Period : Day
Illumina Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Duration : Period : Week
Illumina Technical Analysis Chart | ILMN | US4523271090 | 4-Traders